OCB congratulates glaucoma specialist Ambika Hoguet, MD, who coauthored an American Academy of Ophthalmology paper assessing the effectiveness of SFT laser in the treatment of glaucoma. The article was published in January 2024 issue of the journal Ophthalmology.
Among the study’s conclusions were that SLT is an effective method with minimal safety concerns for IOP control in patients with ocular hypertension, primary open angle glaucoma (POAG), pigmentary glaucoma, pseudoexfoliation glaucoma, and juvenile open-angle glaucoma. The article concluded that evidence indicates that SLT is equivalent to glaucoma medications for IOP control as a first-line treatment for POAG and ocular hypertension. SLT Laser may be more cost-effective than medications, and it may provide better long-term disease control than medications. In patients with POAG that is well controlled with medications, evidence suggests that SLT can decrease or completely replace medications needed for IOP control.
